Javelin Medical
Filter Implant for Stroke Prevention
Company Overview
Snapshot
Founded in May 2012 by Ofer Yodfat and Guy Shinar, Javelin Medical operates with 11–50 employees. The company is currently in the Pre-Funding stage and is developing its Vine device, a permanent filter designed to prevent strokes, which is undergoing clinical trials in Europe.
Business overview
Javelin Medical is a Health Tech & Life Sciences company focused on developing medical devices for stroke prevention. Its core product, Vine, is a permanent filter designed for implantation in the carotid arteries to intercept blood clots and prevent strokes in individuals with abnormal heart rhythm (atrial fibrillation). The device is implanted through a minimally invasive procedure and is currently being evaluated in the CAPTURE II study across several European countries, targeting healthcare providers, doctors, clinics, and hospitals within the cardiology and neurology sectors.
Strategic signal
In May 2019, Javelin Medical's novel carotid filter for stroke prevention in atrial fibrillation was highlighted, indicating the company's progress in clinical development and its potential to address a significant medical need. This signals to investors a focus on innovative medical device solutions with a clear clinical application and market opportunity within the cardiovascular health sector.
Company Intelligence Q&A
- What is Javelin Medical's primary product?
- Javelin Medical's primary product is Vine, a permanent filter designed to be implanted in the carotid arteries to prevent strokes by intercepting blood clots in individuals with atrial fibrillation.
- When was Javelin Medical founded?
- Javelin Medical was founded in May 2012.
- Who are the founders of Javelin Medical?
- Javelin Medical was co-founded by Ofer Yodfat, who serves as CMO, and Guy Shinar, who serves as CTO.
- What is the current development stage of the Vine device?
- The Vine device is currently in the clinical trial product stage and is available for individuals with atrial fibrillation through participation in the CAPTURE II study in several European countries.
- What market does Javelin Medical primarily target?
- Javelin Medical primarily targets the European market, specifically focusing on healthcare providers, doctors, clinics, and hospitals within the cardiology and neurology sectors for stroke prevention.